Bristol Myers Squibb (BMY) Stock Price, News & Analysis

Company Overview

Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing and delivering innovative medicines for patients with serious diseases. The company’s research and development efforts are primarily focused on oncology, immunology, cardiovascular disease and fibrosis. Through a combination of internal research programs and strategic acquisitions, Bristol Myers Squibb aims to address critical unmet medical needs and improve long-term health outcomes.

The company’s portfolio includes a range of marketed therapies such as Opdivo for multiple cancers, Eliquis for stroke prevention in atrial fibrillation and various immunology treatments. Following its acquisition of Celgene, Bristol Myers Squibb also integrated several hematology and oncology products, further strengthening its position in specialized medicine. Its pipeline features both small molecules and biologics, with ongoing clinical trials exploring novel mechanisms of action across a spectrum of disease areas.

Founded in 1989 through the merger of Bristol-Myers Company and Squibb Corporation—and tracing its roots back to the mid-19th century—Bristol Myers Squibb is headquartered in New York and operates in more than 60 countries worldwide. The company maintains research facilities in North America, Europe and Asia, and collaborates with academic institutions, biotechnology firms and other pharmaceutical companies to advance scientific innovation. Under the leadership of Chief Executive Officer Giovanni Caforio, Bristol Myers Squibb continues to pursue a patient-centric strategy aimed at delivering transformative therapies on a global scale.

Key Stats

• Today's Range: $46.50 to $47.17
• 50-Day Range: $43.37 to $48.99
• 52-Week Range: $42.96 to $63.33
• Volume: 8.23 million shs
• Average Volume: 9.28 million shs
• Market Capitalization: $95.84 billion
• P/E Ratio: 18.99
• Dividend Yield: 5.27%
• Price Target: $56.38
• Consensus Rating: Hold

Bristol Myers Squibb Stock Analysis - MarketRank™

Bristol Myers Squibb scored higher than 98% of companies evaluated by MarketBeat, and ranked 36th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Bristol Myers Squibb has received a consensus rating of Hold. The company's average rating score is 2.24, and is based on 4 buy ratings, 15 hold ratings, and 1 sell rating.

Upside Potential

Bristol Myers Squibb has a consensus price target of $56.38, representing about 19.7% upside from its current price of $47.08.

Amount of Analyst Coverage

Bristol Myers Squibb has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -9.64%

Earnings Growth

Earnings for Bristol Myers Squibb are expected to decrease by -9.64% in the coming year, from $6.74 to $6.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bristol Myers Squibb is 18.99, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 277.91.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bristol Myers Squibb is 18.99, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.08.

Price to Earnings Growth Ratio

Bristol Myers Squibb has a PEG Ratio of 2.39. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Bristol Myers Squibb has a P/B Ratio of 5.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.46% of the float of Bristol Myers Squibb has been sold short.

Short Interest Ratio / Days to Cover

Bristol Myers Squibb has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bristol Myers Squibb has recently decreased by 3.98%, indicating that investor sentiment is improving.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Leadership

Bristol Myers Squibb is a leading dividend payer. It pays a dividend yield of 5.31%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Bristol Myers Squibb has been increasing its dividend for 17 years.

Dividend Coverage

The dividend payout ratio of Bristol Myers Squibb is 100.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Bristol Myers Squibb will have a dividend payout ratio of 40.72% next year. This indicates that Bristol Myers Squibb will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -2.30

Percentage of Shares Shorted

1.46% of the float of Bristol Myers Squibb has been sold short.

Short Interest Ratio / Days to Cover

Bristol Myers Squibb has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bristol Myers Squibb has recently decreased by 3.98%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.16

News Sentiment

Bristol Myers Squibb has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 41 news articles for Bristol Myers Squibb this week, compared to 59 articles on an average week.

Search Interest

Only 99 people have searched for BMY on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.

MarketBeat Follows

28 people have added Bristol Myers Squibb to their MarketBeat watchlist in the last 30 days. This is an increase of 8% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bristol Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,667,199.00 in company stock.

Percentage Held by Insiders

Only 0.09% of the stock of Bristol Myers Squibb is held by insiders.

Percentage Held by Institutions

76.41% of the stock of Bristol Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BMY Stock Analysis - Frequently Asked Questions

How have BMY shares performed this year?

Bristol Myers Squibb's stock was trading at $56.56 at the beginning of the year. Since then, BMY stock has decreased by 16.8% and is now trading at $47.0840.

How were Bristol Myers Squibb's earnings last quarter?

Bristol Myers Squibb Company (NYSE:BMY) issued its quarterly earnings results on Thursday, July, 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. The company's quarterly revenue was up .6% compared to the same quarter last year.
Read the conference call transcript.

When did Bristol Myers Squibb's stock split?

Shares of Bristol Myers Squibb split on the morning of Thursday, June 26th 2014.The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were issued to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

How will Bristol Myers Squibb's stock buyback program work?

Bristol Myers Squibb's Board of Directors initiated a stock repurchase plan on Thursday, December 7th 2023, which permits the company to repurchase $3,000,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 2.9% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board believes its stock is undervalued.

Does Bristol Myers Squibb have any subsidiaries?

Bristol Myers Squibb subsidiaries include MyoKardia, Forbius, Celgene, IFM Therapeutics, Cormorant Pharmaceuticals, Padlock Therapeutics, Cardioxyl Pharmaceuticals, and others.

Who are Bristol Myers Squibb's major shareholders?

Top institutional investors of Bristol Myers Squibb include Vanguard Group Inc. (9.58%), State Street Corp (4.65%), Charles Schwab Investment Management Inc. (3.48%) and Geode Capital Management LLC (2.27%). Insiders that own company stock include Giovanni Caforio, David V Elkins, Samit Hirawat, Christopher S Boerner, Rupert Vessey, Theodore R Samuels II, Ann Powell, Phil M Holzer, Benjamin Hickey, Robert M Plenge and Bartie Wendy Short.
View institutional ownership trends.

How do I buy shares of Bristol Myers Squibb?

Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bristol Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bristol Myers Squibb investors own include Chevron (CVX), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW), Yum! Brands (YUM) and Toronto Dominion Bank (TD).

Company Calendar

• Record date for 8/1 Dividend: 7/03/2025
• Ex-Dividend for 8/1 Dividend: 7/03/2025
• Last Earnings: 7/31/2025
• Dividend Payable: 8/01/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:BMY
• CIK: 14272
• Web: www.bms.com
• Phone: (212) 546-4000
• Fax: 212-546-4020
• Employees: 34,100
• Year Founded: 1887

Price Target and Rating

• Average Price Target for Bristol Myers Squibb: $56.38
• High Price Target: $73.00
• Low Price Target: $34.00
• Potential Upside/Downside: +19.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.24
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.48
• Trailing P/E Ratio: 18.99
• Forward P/E Ratio: 6.99
• P/E Growth: 2.39
• Net Income: -$8.95 billion
• Net Margins: 10.58%
• Pretax Margin: 13.82%
• Return on Equity: 80.04%
• Return on Assets: 14.69%

Debt

• Debt-to-Equity Ratio: 2.54
• Current Ratio: 1.21
• Quick Ratio: 1.11

Sales & Book Value

• Annual Sales: $48.30 billion
• Price / Sales: 1.98
• Cash Flow: $5.94 per share
• Price / Cash Flow: 7.93
• Book Value: $8.08 per share
• Price / Book: 5.83

Miscellaneous

• Outstanding Shares: 2,035,440,000
• Free Float: 2,033,604,000
• Market Cap: $95.84 billion
• Optionable: Optionable
• Beta: 0.35